KCM
ALNY icon

Kennedy Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kennedy Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
3,607
+104
+3% +$31.4K 0.02% 506
2026
Q1 		$1.16M Buy
3,503
+288
+9% +$98K 0.02% 474
2025
Q4 		$1.28M Sell
3,215
-5
-0.2% -$2.21K 0.03% 460
2025
Q3 		$1.47M Buy
3,220
+1,552
+93% +$632K 0.03% 475
2025
Q2 		$544K Buy
1,668
+127
+8% +$35.1K 0.01% 542
2025
Q1 		$416K Buy
1,541
+6
+0.4% +$1.54K 0.01% 591
2024
Q4 		$361K Sell
1,535
-944
-38% -$248K 0.01% 645
2024
Q3 		$682K Buy
2,479
+301
+14% +$78.4K 0.02% 624
2024
Q2 		$529K Buy
2,178
+630
+41% +$99.5K 0.01% 636
2024
Q1 		$231K Buy
+1,548
New +$258K ﹤0.01% 693
2021
Q2 		– Sell
-1,442
Closed -$204K – 627
2021
Q1 		$204K Buy
+1,442
New +$217K ﹤0.01% 647

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's ALNY Position: Q2 2026 in Review

Kennedy Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 3% in Q2 2026, buying an estimated $31.4K and bringing the position to 3,607 shares worth $1.09M. The position accounts for 0.02% of the portfolio, ranked #506.

Kennedy Capital Management first reported a position in ALNY in Q1 2021 and has held it in 11 quarters since. The position peaked at $1.47M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Kennedy Capital Management held 3,607 shares of Alnylam Pharmaceuticals worth $1.09M as of Q2 2026.
  • Kennedy Capital Management bought 104 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $31.4K.
  • Alnylam Pharmaceuticals made up 0.02% of Kennedy Capital Management's portfolio in Q2 2026, its #506 holding.
  • Kennedy Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
  • Kennedy Capital Management's Alnylam Pharmaceuticals position peaked at $1.47M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.